← Back to Search

Protease Inhibitor

Anti-HIV Drug Combination for HIV

Q: To whom does this experiment extend an invitation?

<p>This clinical trial seeks 80 <a href="https://www.withpower.com/clinical-trials/hiv">HIV</a>+ individuals aged 16 and up, each of whom must acceptably adhere to the following criteria: practice abstinence or employ contraceptives such as condoms; have a CD4 count exceeding 75 cells/mm3 and viral load above 5,000 copies/ml; secure parental consent if under 18 years old; discontinue <a href="https://www.withpower.com/clinical-trials/all">all</a> anti-HIV medications with exception to those administered during study.</p>

Phase 2

Waitlist Available

Research Sponsored by Merck Sharp & Dohme Corp.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing a new HIV treatment regimen to see if it's safe and effective.

Who is the study for?

This trial is for HIV-positive individuals aged 16 or older with a CD4 cell count over 75 cells/mm3 and viral load above 5,000 copies/ml. Participants must not be pregnant, breastfeeding, have certain severe health conditions, or have used specific medications recently. They should agree to use barrier contraception and stop all other anti-HIV drugs.Check my eligibility

What is being tested?

The study tests the safety and effectiveness of taking a combination of anti-HIV drugs—indinavir (IDV), ritonavir (RTV), stavudine (d4T), and lamivudine (3TC)—twice daily in reducing HIV blood levels.See study design

What are the potential side effects?

Potential side effects may include digestive issues, changes in liver function, allergic reactions to the medication components, fatigue, headaches, and possible interactions with other drugs.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme Corp.Lead Sponsor

2,286 Previous Clinical Trials

4,581,742 Total Patients Enrolled

Merck Sharp & Dohme LLCLead Sponsor

3,886 Previous Clinical Trials

5,054,491 Total Patients Enrolled

Media Library

Indinavir (Protease Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT00002241 — Phase 2

Human Immunodeficiency Virus Infection Research Study Groups:

Human Immunodeficiency Virus Infection Clinical Trial 2023: Indinavir Highlights & Side Effects. Trial Name: NCT00002241 — Phase 2

Indinavir (Protease Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00002241 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any medical centers in North America that are currently conducting this trial?

"This clinical investigation is being conducted across 18 different sites, including Kaiser Foundation Hospital in San Francisco, Montefiore Med Ctr in Bronx and CRI New England in Brookline."

Answered by AI

Does this clinical study include participants of advanced age?

"Prospective applicants aged between 16 and 65 are eligible for this trial. Moreover, there are 108 trials available to minors and 353 open to seniors."

Answered by AI

To whom does this experiment extend an invitation?

"This clinical trial seeks 80 HIV+ individuals aged 16 and up, each of whom must acceptably adhere to the following criteria: practice abstinence or employ contraceptives such as condoms; have a CD4 count exceeding 75 cells/mm3 and viral load above 5,000 copies/ml; secure parental consent if under 18 years old; discontinue all anti-HIV medications with exception to those administered during study."

Answered by AI

Is this therapy viable in terms of safety and efficacy?

"Our risk assessment team at Power assigned a rating of 2 to this treatment due the lack of efficacy data and presence of safety information, as it is only in Phase 2."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily

2024. "Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00002241.

All > Hiv Infection > Ic